Gastroesophageal reflux disease (GERD) is still an important clinical problem. Continuing efforts are being made to establish a classification of the condition that would allow improved communications for both clinical and research purposes. In medical treatment, the trends are toward proton-pump inhibitor therapy at all stages of GERD, calling into question the role of endoscopy for tailoring individual therapy. Arguments against the use of H. pylori eradication therapy in GERD have gained importance. Surgeons are continuing to report excellent results with fundoplication, but careful studies are needed to prove whether antireflux surgery is really capable of saving costs, as its proponents claim.
Barrett's esophagus is still a topic of lively interest. Since there is no method of primary prevention, endoscopy has a crucial role in detecting affected patients and guiding them toward one of the various surveillance strategies - which are not yet clearly established. The debate over short-segment Barrett's esophagus, and especially over „microscopic” Barrett's esophagus (at the squamocolumnar junction), has not yet been resolved. However, there is now less doubt that GERD is a condition associated with a substantially higher risk for the development of esophageal adenocarcinoma.
Given this risk of malignant transformation, there is continuing competition between different ablation techniques; however, careful data from much larger populations will be needed before ablation reaches the stage of broad clinical application. Until specific guidelines become available, patients with Barrett's esophagus should receive endoscopic follow-up until it can be ascertained which individuals are at risk for cancer and require ablation of Barrett's mucosa.
References (Key References are highlighted)
-
1
Trudgill
NJ, Kapur KC, Riley SA.
Familial clustering of reflux symptoms.
Am J Gastroenterol.
1999;
94
1172-1178
-
2
Contractor QQ, Akhtar SS, Contractor TQ.
Endoscopic esophagitis and gastroesophageal flap valve.
J Clin Gastroenterol.
1999;
28
233-237
-
3
Lundell
L, Dent J, Bennett JR, et al.
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification.
Gut.
1999;
45
172-180
-
4
Stal P, Lindberg G, Ost A, et al.
Gastroesophageal reflux in healthy subjects: significance of endoscopic findings, histology, age and sex.
Scand J Gastroenterol.
1999;
34
121-128
-
5
Lind T, Havelund T, Lundell L, et al.
On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled trial.
Aliment Pharmacol Ther.
1999;
13
907-914
-
6
Blustein
PK, Beck PL, Meddings JB, et al.
The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms.
Am J Gastroenterol.
1998;
93
2508-2512
-
7
Sonnenberg A, Delco F, El-Serag HB.
Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis.
Dig Dis Sci.
1998;
43
1001-1008
-
8
Wu JCY, Sung JJY, Ng EKW, et al.
Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East.
Am J Gastroenterol.
1999;
94
1790-1794
-
9
El-Serag HB, Sonnenberg A, Jamal MM, et al.
Corpus gastritis is protective against reflux oesophagitis.
Gut.
1999;
45
181-185
-
10
Vicari JJ, Peek RM, Falk GW, et al.
The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease.
Gastroenterology.
1998;
115
50-57
-
11
Holtmann G, Cain C, Malfertheiner P.
Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton-pump inhibitor pantoprazole.
Gastroenterology.
1999;
117
11-16
-
12
Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al.
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
Am J Gastroenterol.
1999;
94
884-887
-
13
Lundell
L, Miettinen P, Myrvold HE, et al.
Lack of effect of acid suppression therapy on gastric atrophy.
Gastroenterology.
1999;
117
319-326
-
14
Peters
JH, DeMeester TR, Crookes P, et al.
The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: prospective evaluation of 100 patients with “typical” symptoms.
Ann Surg.
1998;
228
40-50
-
15
Van der Peet DL, Klinkenberg-Knol EC EC, Eijsbouts QA, et al.
Laparoscopic Nissen fundoplication for the treatment of gastroesophageal reflux disease (GERD): surgery after extensive conservative treatment.
Surg Endosc.
1998;
12
1159
-
16
Csendes A, Braghetto A, Burdiles P, et al.
Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation.
Surgery.
1998;
123
645-657
-
17
El-Sarag
HB, Sonnenberg A.
Outcome of erosive reflux esophagitis after Nissen fundoplication.
Am J Gastroenterol.
1999;
94
1771-1776
-
18
Murphy PP, Ballinger PJ, Massey BT, et al.
Discrete ulcers in Barrett's esophagus: relationship to acute gastrointestinal bleeding.
Endoscopy.
1998;
30
367-370
-
19
Lagergren
J, Bergström R, Lindgren A, Nyrén O.
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.
N Engl J Med.
1999;
340
825-831
-
20
Bytzer P, Christensen PB, Damkier P, et al.
Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.
Am J Gastroenterol.
1999;
94
86-91
-
21
Eloubeidi MA, Provenzale D.
Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy.
Am J Gastroenterol.
1999;
94
937-943
-
22
El-Serag HB, Sonnenberg A, Jamal MM, et al.
Characteristics of intestinal metaplasia in the gastric cardia.
Am J Gastroenterol.
1999;
94
622-627
-
23
Hirota WK, Loughney TM, Lazas DJ, et al.
Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data.
Gastroenterology.
1999;
116
277-285
-
24
Pereira AD, Suspiro A, Chaves P, et al.
Short segments of Barrett's epithelium and intestinal metaplasia in normal appearing esophagogastric junctions: the same or two different entities?.
Gut.
1998;
42
659-662
-
25
Voutilainen
M, Farkkila M, Juhola M, et al.
Spezialized columnar epithelium of the esophagogastric junction: prevalence and associations (The Central Finland Endoscopy Study Group).
Am J Gastroenterol.
1999;
94
913-918
-
26
Byrne JP, Bhatnagar S, Hamid B, et al.
Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy.
Am J Gastroenterol.
1999;
94
98-103
-
27
Falk GW, Rice TW, Goldblum JR, Richter JE.
Jumbo forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia.
Gastrointest Endosc.
1999;
49
170-176
-
28
Morales TG, Bhattacharyya A, Camargo E, et al.
Methylene blue staining for intestinal metaplasia of the gastric cardia with follow-up dysplasia.
Gastrointest Endosc.
1998;
48
26-31
-
29
Gueltrud M, Herrera I.
Acetic acid improves identification of remnant islands of Barrett's epithelium after endoscopic therapy.
Gastrointest Endosc.
1998;
47
512-515
-
30
Smith AM, Maxwell-Armstrong CA, Welch NT, Scholefield JH.
Surveillance for Barrett's oesophagus in the UK.
Br J Surg.
1999;
86
276-280
-
31
O'Connor JB, Falk GW, Richter JE.
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus.
Am J Gastroenterol.
1999;
94
2037-2042
-
32
Gulizia JM, Wang H, Antonioli D, et al.
Proliferative characteristics of intestinal mucosa in the distal esophagus and gastroesophageal junction (short-segment esophagus): a case-control study.
Hum Pathol.
1999;
30
412-418
-
33
Ouatu-Lescar
R, Fitzgerald RC, Triadafilopoulos G.
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.
Gastroenterology.
1999;
117
327-335
-
34
Ouatu-Lescar R, Triadafilopoulos G.
Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Am J Gastroenterol.
1998;
93
711-716
-
35
Cooper BT, Neumann CS, Cox NA, Iqbal TH.
Continuous treatment with omeprazole 20 mg for up to 6 years in Barrett's oesophagus.
Aliment Pharmacol Ther.
1998;
12
893-897
-
36
Low DE, Levine DS, Dail DH, Kozarek RA.
Histological and anatomic changes in Barrett's esophagus after antireflux surgery.
Am J Gastroenterol.
1999;
94
80-85
-
37
Peters FTM, Ganesh S, Kuipers EJ, et al.
Endoscopic regression of Barrett's oesophagus during omeprazole treatment: a randomised double-blind study.
Gut.
1999;
45
489-494
-
38
Kovacs
BJ, Chen YK, Lewis TD, et al.
Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression.
Gastrointest Endosc.
1999;
49
547-553
-
39
Byrne JP, Armstrong GR, Attwood SEA.
Restoration of normal squamous lining in Barrett's esophagus by argon beam plasma coagulation.
Am J Gastroenterol.
1998;
93
1810-1815
-
40
Mork H, Barth T, Kreipe HH, et al.
Reconstitution of squamous epithelium in Barrett's oesophagus with endoscopic argon plasma coagulation: a prospective study.
Scand J Gastroenterol.
1998;
33
1130-1134
-
41
Grade AJ, Shah IA, Medlin SM, Ramirez FC.
The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus.
Gastrointest Endosc.
1999;
50
18-22
-
42
Van Laethem JL, Cremer M, Peny MO, et al.
Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid-term results.
Gut.
1998;
43
747-751
-
43
Gossner
L, May A, Stolte M, et al.
KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus.
Gastrointest Endosc.
1999;
49
8-12
-
44
Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE.
Laser and multipolar electrocoagulation ablation in early Barrett's adenocarcinoma: long-term follow-up.
Gastrointest Endosc.
1999;
49
442-446
-
45
Overholt BF, Panjehpour M, Haydek JM.
Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.
Gastrointest Endosc.
1999;
49
1-7
H. KoopM.D.
Dept. of Medicine II
Klinikum Buch
Karower Strasse 11
13122 Berlin
Germany
Phone: + 49-30-9401-4262
Email: hkoop@klinikumbuch.de
